"But still we had 22% overall MACE reduction if you usu CHF instead of stroke,.... which is still pretty good,... but WOW numbers for CKD!"

The pre-specified primary endpoint was the 3-point MACE composite of CVD death, non-fatal MI, non-fatal stroke. CHF was not part of the pre-specified primary endpoint. My point of doing that 2X CKD patient exercise was to see how doubling the number of CKD patients would affect the 3-point MACE primary endpoint (CVD death, non-fatal MI, non-fatal stroke). If that hypothetical 22% RRR for 3-point MACE in my 2X CKD patient exercise would have been statistically significant (p<0.05), BETonMACE would have been considered a success instead of being stuck w/ a non-significant p=0.11 "failure." 

And BTW Paladin....as Cabel realized and pointed out, those 48 (13 vs. 35) were the number of observed 3-point MACE events in the apabetalone vs. placebo CKD sub-group, not the number of patients (124 vs. 164). 

BDAZ